Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality

被引:26
|
作者
Hernandez-Torres, Alicia
Garcia-Vazquez, Elisa [1 ]
Gomez, Joaquin [1 ]
Canteras, Manuel [2 ]
Ruiz, Joaquin
Yaguee, Genoveva
机构
[1] Univ Murcia, Dept Internal Med, Fac Med, Murcia, Spain
[2] Univ Murcia, Dept Biostat, Fac Med, Murcia, Spain
来源
MEDICINA CLINICA | 2012年 / 138卷 / 15期
关键词
Acinetobacter baumannii; Multidrug resistant; Infection; Mortality; Treatment; NOSOCOMIAL INFECTIONS; CLINICAL-FEATURES; COLISTIN; BACTEREMIA; RIFAMPICIN; EPIDEMIOLOGY; COMBINATION; TIGECYCLINE; MONOTHERAPY; IMIPENEM;
D O I
10.1016/j.medcli.2011.06.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objective: To analyse factors related to mortality and influence of antibiotic treatment on outcome in patients with nosocomial infection due to multidrug and carbapenem-resistant Acinetobacter baumannii (MDR-C AB). Patients and methods: Observational and prospective study of a cohort of adult patients with MDR-C AB infection. Data collection from clinical records was done according to a standard protocol (January 2007 through June 2008). Patients with MDR-C AB infection were identified by review of results of microbiology cultures from the hospital microbiology laboratory. Epidemiological and clinical variables and predictors of mortality were analysed. Results: 24 out of 101 cases were considered colonizations and 77 infections (27 bacteraemia); global mortality in infected patients was 49% (18 cases with bacteraemia and 20 with no bacteraemia). In the multivariate analysis, including the 77 cases of infection, the prognosis factors associated with mortality were age (OR 1.09; 95% Cl 1.02-1.2), McCabe 1 (OR 33.98; 95% Cl 4.33-266.85), bacteraemia (OR 9.89; 95% Cl 1.13-86.13), inadequate empiric treatment (OR 16.7; 95% Cl 2.15-129.79), and inadequate definitive treatment (OR 26.29; 95% Cl 1.45-478.19). In the multivariate analysis including the 57 cases of infection with adequate definitive treatment, the prognosis factors associated with mortality were McCabe 1 (OR 24.08:95% Cl 3.67-157.96) and monotherapy versus combined treatment (OR 7.11; 95% Cl 1.63-30.99). Conclusions: Our cohort of patients with MDR-C AB infection is characterised by a very high mortality (49%); the severity of patients and inadequate treatment or monotherapy are statistically associated with mortality. 2011 (C) Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:650 / 655
页数:6
相关论文
共 50 条
  • [11] Gut colonization by multidrug-resistant and carbapenem-resistant Acinetobacter baumannii in neonates
    S. Roy
    R. Viswanathan
    A. Singh
    P. Das
    S. Basu
    European Journal of Clinical Microbiology & Infectious Diseases, 2010, 29 : 1495 - 1500
  • [12] The Rise of Carbapenem-Resistant Acinetobacter baumannii
    Evans, Benjamin A.
    Hamouda, Ahmed
    Amyes, Sebastian G. B.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (02) : 223 - 238
  • [13] Ri sk factors for early mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteraemia
    Lee, Chan Mi
    Kim, Chung -Jong
    Kim, Seong Eun
    Park, Kyung-Hwa
    Bae, Ji Yun
    Choi, Hee Jung
    Jung, Younghee
    Lee, Seung Soon
    Choe, Pyoeng Gyun
    Park, Wan Beom
    Kim, Eu Suk
    Song, Je Eun
    Kwak, Yee Gyung
    Lee, Sun Hee
    Lee, Shinwon
    Cheon, Shinhye
    Kim, Yeon Sook
    Kang, Yu Min
    Bang, Ji Hwan
    Jung, Sook-In
    Song, Kyoung-Ho
    Bin Kim, Hong
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 31 : 45 - 51
  • [14] Predictive modeling of mortality in carbapenem-resistant Acinetobacter baumannii bloodstream infections using machine learning
    Ozdede, Murat
    Zarakolu, Pinar
    Metan, Gokhan
    Eser, Ozgen Koseoglu
    Selimova, Cemile
    Kizilkaya, Canan
    Elmali, Ferhan
    Akova, Murat
    JOURNAL OF INVESTIGATIVE MEDICINE, 2024, 72 (07) : 684 - 696
  • [15] Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
    August, Benjamin
    Matlob, Andrew
    Kale-Pradhan, Pramodini B.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (07) : 735 - 741
  • [16] Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections
    Song, Joon Young
    Cheong, Hee Jin
    Choi, Won Suk
    Heo, Jung Yeon
    Noh, Ji Yun
    Kim, Woo Joo
    JOURNAL OF MEDICAL MICROBIOLOGY, 2011, 60 (05) : 605 - 611
  • [17] Impact of carbapenem-resistant Acinetobacter baumannii infections on acute pancreatitis patients
    Wu, Di
    Huang, Yilin
    Ding, Junjie
    Jia, Yan
    Liu, Huanmiao
    Xiao, Jie
    Peng, Jie
    PANCREATOLOGY, 2022, 22 (02) : 194 - 199
  • [18] Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections
    Saballs, Mireia
    Pujol, Miquel
    Tubau, Fe
    Pena, Carmen
    Montero, Abelardo
    Dominguez, M. Angeles
    Gudiol, Francesc
    Ariza, Javier
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (03) : 697 - 700
  • [19] Factors associated with mortality in ventilator associated pneumonia of multidrug resistant acinetobacter baumannii
    Sengul, Aysun
    Sengul, Erkan
    Baris, Serap Argun
    Hayirlioglu, Nuket
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [20] New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections
    Isler, Burcu
    Doi, Yohei
    Bonomo, Robert A.
    Paterson, David L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (01)